Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1434-9949
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results ; day:8 ; month:6 ; year:2022 ; pages:1-13
Clinical rheumatology ; (8.6.2022), 1-13

Creator
Coates, Laura C.
Mease, Philip
Kronbergs, Andris
Helt, Cameron
Sandoval, David
Park, So Young
Combe, Bernard
Nash, Peter
Deodhar, Atul
Contributor
SpringerLink (Online service)

DOI
10.1007/s10067-022-06218-8
URN
urn:nbn:de:101:1-2022091502143117236789
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Coates, Laura C.
  • Mease, Philip
  • Kronbergs, Andris
  • Helt, Cameron
  • Sandoval, David
  • Park, So Young
  • Combe, Bernard
  • Nash, Peter
  • Deodhar, Atul
  • SpringerLink (Online service)

Other Objects (12)

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H

Spirit and form

Spirit and form

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Spirit animal - animal spirit

Anthologie | Erzählende Literatur: Gegenwartsliteratur ab 1945

Spirit animal - animal spirit

"Spirits of air and earth and sea", an air and chorus of spirits

Abschnitt

"Spirits of air and earth and sea", an air and chorus of spirits

Spirit

Spirit

456-457 [Rezension] Come, Arnold B., Human spirit and Holy Spirit

Aufsatz

456-457 [Rezension] Come, Arnold B., Human spirit and Holy Spirit

Animal Spirits and Credit Cycles

Arbeitspapier

Animal Spirits and Credit Cycles

Brahms and the German spirit

Brahms and the German spirit

The letter and the spirit

Grafik

The letter and the spirit

Origen and the Holy Spirit

Hochschulschrift

Origen and the Holy Spirit

Related objects